Side-by-side comparison of AI visibility scores, market position, and capabilities
CUTISS is a Swiss biotech developing personalized dermo-epidermal skin grafts from patient cells for large skin defect treatment; denovoSkin product reduces reliance on painful autografts; raised CHF 30M+ in funding;
CUTISS is a Swiss clinical-stage biotechnology company founded in 2017 as a spin-off from the University Children's Hospital Zurich, focused on developing personalized bioengineered skin grafts for patients with large skin defects caused by severe burns, rare congenital skin diseases, and traumatic wounds. The company's lead product, denovoSkin, is a dermo-epidermal skin graft manufactured by combining a small biopsy of a patient's own skin cells with a proprietary hydrogel scaffold — which is then cultured to grow a full-thickness skin equivalent containing both the dermis (dermal layer) and epidermis (outer layer). Because the graft uses the patient's own cells, it avoids immune rejection without the need for immunosuppression.
DNAnexus is the leading precision health data cloud, managing 65+ petabytes of biomedical data for 12,000+ users across 48 countries; $200M Series I led by Blackstone Growth; serves 7 of top 10 pharma and 8 of top 10 diagnostics companies.
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a secure, scalable, and regulatory-compliant cloud environment where pharmaceutical companies, genomics labs, biobanks, health systems, and research institutions can store, analyze, and share multimodal biomedical data — including genomic sequences, clinical records, imaging, and real-world evidence. The platform is purpose-built for the data types, compliance requirements, and computational workloads unique to biomedical research and precision medicine development.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.